Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Retains Velcade U.S. Rights; J&J Picks Up Half Of R&D Costs

Executive Summary

Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs
Advertisement

Related Content

Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
Millennium Increasing Integrilin Sales Force, Emphasizing Earlier Use
Millennium Increasing Integrilin Sales Force, Emphasizing Earlier Use
J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes
J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes
Advertisement
UsernamePublicRestriction

Register

PS042098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel